NRGN and Alzheimer disease: Taken together, these findings reinforce the clinical evidence that CSF and blood exosomes Ng can be used as a cognitive biomarker for AD and MCI-AD, but it is still difficult to identify the different stages of the disease through the specific range of Ng values, therefore, further studies are needed to define the Ng values for diagnosis of MCI-AD and AD.